Core Viewpoint - Analysts expect IBM to report quarterly earnings of $4.33 per share, reflecting a year-over-year increase of 10.5%, with revenues projected at $19.2 billion, up 9.4% from the previous year [1] Earnings Estimates - Changes in earnings estimates are crucial for predicting investor reactions, with empirical research showing a strong correlation between earnings estimate revisions and short-term stock performance [2] Key Metrics Projections - Analysts project 'Revenue- Software' to be $8.90 billion, indicating a year-over-year change of +12.4% [4] - 'Revenue- Consulting' is expected to reach $5.43 billion, reflecting a +5% change from the prior year [4] - 'Revenue- Other' is estimated at $32.55 million, showing a +12.3% year-over-year change [4] - 'Revenue- Infrastructure' is forecasted at $4.67 billion, suggesting a +9.8% increase year over year [5] - 'Revenue- Infrastructure Support' is projected to be $1.31 billion, with a +0.7% change [5] - 'Revenue- Transaction Processing' is expected to reach $2.55 billion, indicating a +6.4% change [5] - 'Revenue- Hybrid Infrastructure' is anticipated to be $3.36 billion, reflecting a +12.1% change [6] Segment Profit Projections - 'Segment Profit- Software' is expected to reach $3.62 billion, compared to $3.10 billion in the same quarter last year [6] - 'Segment Profit- Infrastructure' is projected at $1.16 billion, up from $1.06 billion year over year [6] - 'Segment Profit- Financing' is estimated at $97.25 million, compared to $94.00 million in the previous year [7] - 'Segment Profit- Consulting' is expected to be $685.71 million, up from $606.00 million in the same quarter last year [7] Stock Performance - Over the past month, IBM shares have recorded a return of -3.3%, while the Zacks S&P 500 composite has changed by +0.6% [7]

Core Viewpoint - Analysts project that Raymond James Financial, Inc. (RJF) will report quarterly earnings of $2.87 per share, reflecting a 2.1% decline year over year, while revenues are expected to increase by 5.4% to $3.73 billion [1]. Earnings Estimates - The consensus EPS estimate for the quarter has been adjusted upward by 0.9% over the past 30 days, indicating a reassessment by covering analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock performance [3]. Revenue Projections - Analysts predict 'Revenues- Other' to reach $41.94 million, a 7.5% increase from the prior-year quarter [5]. - 'Net Revenues- Total brokerage revenues' are expected to be $583.97 million, reflecting a 4.5% increase year over year [5]. - 'Revenues- Account and service fees' are projected at $300.41 million, indicating a 12.2% decline year over year [5]. - 'Revenues- Investment banking' is expected to be $276.36 million, a 15% decrease from the previous year [6]. - 'Revenues- Interest income' is forecasted to reach $970.30 million, showing a 5.5% decline year over year [6]. Asset Management Metrics - 'Private Client Group Asset Under Management' is projected to be $1.67 billion, up from $1.49 billion in the same quarter last year [6]. - 'Assets Under Management' is expected to reach $281.46 billion, compared to $243.90 billion a year ago [8]. - 'Total Interest-Earning Assets' is projected at $80.57 billion, an increase from $76.49 billion year over year [8]. Capital Ratios - The average prediction for 'Tier 1 Leverage Ratio' is 12.9%, slightly down from 13.0% a year ago [7]. - The consensus estimate for 'Total Capital Ratio' stands at 24.4%, compared to 25.0% in the previous year [7]. - The estimated 'Tier 1 Capital Ratio' is 23.2%, down from 23.7% reported in the same quarter last year [9]. Stock Performance - Over the past month, Raymond James Financial shares have returned +3.5%, outperforming the Zacks S&P 500 composite's +0.6% change [10].

Core Viewpoint - Analysts expect Microsoft to report quarterly earnings of $3.88 per share, reflecting a year-over-year increase of 20.1%, with revenues projected at $80.23 billion, up 15.2% from the previous year [1] Revenue Estimates - Revenue from 'Productivity and Business Processes' is estimated at $33.49 billion, indicating a year-over-year change of +13.8% [4] - 'Intelligent Cloud' revenue is projected to reach $32.41 billion, showing a significant increase of +26.9% from the prior-year quarter [4] - 'More Personal Computing' revenue is expected to be $14.27 billion, reflecting a decrease of -2.6% compared to the previous year [5] - 'LinkedIn Revenue' is anticipated to be $5.05 billion, indicating a year-over-year increase of +10.1% [5] - Revenue from 'Dynamics products and cloud services' is expected to be $2.23 billion, with a year-over-year change of +16.8% [6] - 'Product Revenue' is projected at $17.80 billion, reflecting a +9.7% change from the prior-year quarter [6] - 'Service and other' revenue is estimated to reach $62.70 billion, indicating a +17.4% change from the previous year [6] Percentage Change in Revenue - The estimated percentage change in revenue for 'Productivity and Business Processes' is 13.8%, compared to 14.0% reported in the same quarter last year [7] - 'Intelligent Cloud' is expected to see a percentage change of 26.9%, up from 19.0% in the previous year [7] - Overall, the forecasted percentage change in revenue is 15.1%, compared to 12.0% from the previous year [8] Unearned Revenue Estimates - Long-term unearned revenue is projected to reach $3.43 billion, up from $2.54 billion reported in the same quarter last year [8] - Short-term unearned revenue is expected to be $51.39 billion, compared to $45.51 billion reported in the same quarter last year [9] Stock Performance - Over the past month, Microsoft shares have decreased by -7.6%, while the Zacks S&P 500 composite has increased by +0.6% [9] - Microsoft holds a Zacks Rank 2 (Buy), indicating a potential to outperform the overall market in the upcoming period [9]

Core Insights - ServiceNow (NOW) is expected to report quarterly earnings of $0.87 per share, reflecting a year-over-year increase of 19.2% [1] - Anticipated revenues for the quarter are projected to be $3.52 billion, also showing a 19.2% increase compared to the previous year [1] Earnings Estimates - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analysts' projections [1][2] - Revisions to earnings estimates are crucial indicators for predicting investor actions regarding the stock [2] Revenue Projections - Analysts estimate 'Revenues- Subscription' to be $3.42 billion, representing a year-over-year change of +19.5% [4] - 'Revenues- Professional services and other' are projected to reach $99.33 million, indicating a +9.2% change from the prior-year quarter [4] Performance Obligations - Current Remaining Performance Obligations (cRPO) - GAAP is estimated at $12.56 billion, up from $10.27 billion a year ago [5] - Remaining Performance Obligations (RPO) - GAAP is projected to be $27.59 billion, compared to $22.30 billion in the same quarter last year [5] Profit Estimates - Gross Profit (Non-GAAP)- Subscription is expected to be $2.85 billion, an increase from $2.42 billion reported in the same quarter last year [6] - Gross Profit (Non-GAAP)- Professional services and other is estimated at $10.21 million, up from $7.00 million a year ago [6] Stock Performance - ServiceNow shares have decreased by -15.8% in the past month, contrasting with the Zacks S&P 500 composite's +0.6% movement [6] - The company holds a Zacks Rank 3 (Hold), suggesting it is expected to closely follow overall market performance in the near term [6]

Core Viewpoint - Analysts forecast AT&T (T) will report quarterly earnings of $0.47 per share, reflecting a year-over-year decline of 13%, with revenues expected to reach $32.73 billion, an increase of 1.3% compared to the previous year [1]. Earnings Estimates - The consensus EPS estimate for the quarter has not changed in the past 30 days, indicating that analysts have not revised their initial projections [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock performance [3]. Revenue Projections - Analysts predict 'Revenues- Communications- Business Wireline' will reach $4.22 billion, a year-over-year decline of 7.1% [5]. - 'Revenues- Communications- Consumer Wireline' is expected to be $3.65 billion, showing a year-over-year increase of 5.4% [5]. - The consensus estimate for 'Revenues- Corporate and Other' is -$34.76 million, indicating a significant decline of 130.2% from the prior-year quarter [5]. - 'Revenues- Communications- Mobility' is projected to be $23.75 billion, reflecting a year-over-year increase of 2.7% [6]. Key Metrics - 'Consumer Wireline - Broadband Connections - Fiber Broadband Connections' is expected to reach 10.41 million, up from 9.33 million in the same quarter last year [6]. - 'Consumer Wireline - Fiber Broadband Net Additions' is estimated at 284.24 thousand, down from 307.00 thousand year-over-year [7]. - 'Consumer Wireline - Broadband Connections - Non Fiber Broadband Connections' is projected at 4.24 million, compared to 4.66 million last year [7]. - 'Consumer Wireline - Broadband Net Additions' is expected to be 151.01 thousand, up from 123.00 thousand year-over-year [8]. - 'Mobility Subscribers - Postpaid phone' is forecasted at 74.24 million, an increase from 72.75 million year-over-year [8]. - 'Mobility Net Additions - Postpaid Phone' is expected to be 439.25 thousand, down from 482.00 thousand in the same quarter last year [9]. - 'Consumer Wireline - Broadband Connections - Broadband' is projected to reach 14.65 million, compared to 13.99 million last year [9]. - 'Mobility - Total Mobility Net Additions' is estimated at 1.02 million, down from 1.81 million in the same quarter last year [10]. Stock Performance - AT&T shares have declined by 4.4% over the past month, contrasting with a 0.6% increase in the Zacks S&P 500 composite, indicating expected underperformance in the near future [11].

Core Insights - Thermo Fisher Scientific Inc. (TMO) is set to release its fourth-quarter 2025 results on January 29, with earnings per share (EPS) expected to be $6.44, reflecting a 5.6% growth year-over-year [1][2][9] Group 1: Earnings and Revenue Estimates - The Zacks Consensus Estimate for TMO's revenues is $11.95 billion, indicating a 4.9% increase from the same quarter last year [2][9] - TMO's earnings have consistently beaten estimates in the past four quarters, with an average surprise of 2.95% [1] Group 2: Segment Performance - The Analytical Instruments segment is anticipated to generate strong sales, particularly from electron microscopy and chromatography and mass spectrometry businesses [4] - The Life-Science Solutions segment is expected to report $2.89 billion in revenues, representing an 11.1% year-over-year improvement, driven by growth in the bioproduction business [10] - Specialty Diagnostics sales are projected to rise by 4.8% year-over-year, supported by new FDA approvals and product launches [9][13] Group 3: Recent Developments - TMO launched several new products, including the Orbitrap Exploris EFOX Mass Detector and new formulations for plasmid DNA production, which are expected to positively impact quarterly revenues [5][7] - The acquisition of Solventum's Purification & Filtration business for approximately $4.0 billion is also anticipated to contribute favorably to TMO's performance [8] - TMO received FDA approvals for multiple diagnostic tests and launched new automated platforms, which are expected to enhance its top-line performance [11][12]

Core Viewpoint - Lazard (LAZ) is anticipated to report a year-over-year decline in earnings due to lower revenues for the quarter ending December 2025, with the consensus outlook indicating potential impacts on its near-term stock price [1][2]. Earnings Expectations - The upcoming earnings report is scheduled for January 29, and if the results exceed expectations, the stock may rise; conversely, a miss could lead to a decline [2]. - The Zacks Consensus Estimate predicts quarterly earnings of $0.64 per share, reflecting an 18% decrease year-over-year, with revenues expected at $810.16 million, down 0.3% from the previous year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised down by 15%, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Lazard aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%, suggesting no recent differing analyst views [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict deviations from consensus estimates, but its predictive power is stronger for positive readings [9][10]. - Lazard currently holds a Zacks Rank of 5, which complicates predictions of an earnings beat [12]. Historical Performance - In the last reported quarter, Lazard exceeded the expected earnings of $0.41 per share by delivering $0.56, resulting in a surprise of +36.59% [13]. - Over the past four quarters, Lazard has consistently beaten consensus EPS estimates [14]. Conclusion - While Lazard does not appear to be a strong candidate for an earnings beat, investors should consider other factors when making decisions regarding the stock ahead of the earnings release [17].

Core Insights - Abbott Laboratories reported fourth-quarter 2025 adjusted EPS of $1.50, aligning with estimates and showing an 11.9% increase from the previous year [1] - Full-year 2025 adjusted EPS was $5.15, reflecting a 10.3% year-over-year growth [1] - The company’s fourth-quarter revenues were $11.46 billion, a 4.4% increase year-over-year, but missed estimates by 2.8% [2] Financial Performance - The GAAP EPS for Q4 was $1.01, down from $5.27 in Q4 2024 [1] - Full-year 2025 worldwide sales reached $44.33 billion, up 5.7% year-over-year, but also missed estimates by 0.6% [2] - Gross profit for Q4 increased by 8.4% to $6.54 billion, with a gross margin expansion of 208 basis points to 57% [9] Segment Performance - Established Pharmaceuticals segment sales rose 9% to $1.38 billion, with organic sales growth of 7.1% [4] - Medical Devices segment sales increased 12.3% to $5.68 billion, driven by strong growth in Electrophysiology, Heart Failure, and Diabetes Care [5] - Nutrition sales declined 8.9% to $1.94 billion, with Pediatric Nutrition down 10.1% and Adult Nutrition down 8.2% [6][7] Future Guidance - For 2026, Abbott projects adjusted EPS between $5.55 and $5.80, with organic sales growth expected to be between 6.5% and 7.5% [11] - The first quarter of 2026 EPS is projected to be between $1.12 and $1.18 [11] Market Reaction - Following the earnings announcement, Abbott's stock fell 5.4% in pre-market trading [3] - The decline in Nutrition sales is attributed to lower sales volumes and strategic pricing actions [12]

Core Viewpoint - UnitedHealth Group (UNH) is expected to report quarterly earnings of $2.09 per share, reflecting a significant year-over-year decline of 69.3%, while revenues are projected to reach $113.26 billion, an increase of 12.4% from the previous year [1] Earnings Estimates - There has been no revision in the consensus EPS estimate for the quarter over the last 30 days, indicating that analysts have maintained their initial forecasts [1][2] Revenue Projections - Analysts estimate 'Revenues- Investment and other income' to be $1.11 billion, down 28.2% year over year [4] - 'Revenues- Services' are forecasted to reach $9.47 billion, indicating a growth of 1.8% from the prior-year quarter [4] - 'Revenues- UnitedHealthcare- Employer & Individual- Global' is expected to be $829.74 million, reflecting a year-over-year increase of 7.1% [4] - The consensus estimate for 'Revenues- Products' stands at $13.86 billion, showing a year-over-year change of 2.9% [5] Customer Profile Metrics - The 'UnitedHealthcare Customer Profile - People Served - Total Commercial - Domestic' is projected to reach 30.02 million, up from 29.73 million a year ago [5] - 'UnitedHealthcare Customer Profile - People Served - Commercial - Domestic - Risk-based' is expected to be 8.45 million, down from 8.85 million [6] - 'UnitedHealthcare Customer Profile - People Served - Commercial - Domestic - Fee-based' is likely to reach 21.57 million, compared to 20.89 million in the same quarter last year [6] - The estimated 'UnitedHealthcare Customer Profile - People Served - Total Community and Senior' is 20.36 million, up from 19.62 million [7] - 'UnitedHealthcare Customer Profile - People Served - Community and Senior - Medicare Advantage' is projected at 8.50 million, compared to 7.85 million a year ago [7] - The average prediction for 'UnitedHealthcare Customer Profile - People Served - Community and Senior - Medicare Supplement (Standardized)' is 4.29 million, slightly down from 4.34 million [8] - 'UnitedHealthcare Customer Profile - People Served - Medicare Part D stand-alone' is expected to be 2.76 million, down from 3.05 million [8] - 'UnitedHealthcare Customer Profile - People Served - Total UnitedHealthcare - Medical' is projected at 50.38 million, compared to 50.68 million in the same quarter last year [9] Stock Performance - UnitedHealth shares have increased by 6.2% over the past month, outperforming the Zacks S&P 500 composite, which rose by 0.7% [10]

Core Insights - Northrop Grumman (NOC) is expected to report quarterly earnings of $7.00 per share, reflecting a 9.6% increase year over year, with revenues projected at $11.62 billion, an 8.7% increase compared to the previous year [1] Earnings Estimates - The consensus EPS estimate has been adjusted upward by 0.1% over the past 30 days, indicating a reassessment by analysts [1][2] - Changes in earnings estimates are crucial for predicting investor reactions and have shown a strong correlation with short-term stock performance [2] Key Metrics Forecast - Analysts predict 'Sales- Mission Systems' to reach $3.43 billion, a 9.2% increase from the prior year [4] - 'Sales- Aeronautics Systems' is expected to be $3.79 billion, indicating a 17.7% increase year over year [4] - 'Sales- Space Systems' is forecasted to reach $3.04 billion, reflecting a 12.2% increase [4] Operating Income Projections - 'Sales- Defense Systems' is expected to be $1.91 billion, showing an 18.1% decrease from the previous year [5] - 'Operating income (loss)- Defense Systems' is projected at $191.92 million, down from $252.00 million year over year [5] - 'Operating income (loss)- Mission Systems' is expected to reach $512.35 million, up from $469.00 million [5] - 'Operating income (loss)- Space Systems' is forecasted at $304.56 million, compared to $275.00 million last year [6] - 'Operating income (loss)- Aeronautics Systems' is expected to be $371.41 million, up from $292.00 million [6] Segment Operating Income Adjustment - The estimate for 'Segment operating income adjustment- FAS/CAS operating adjustment' is projected at $53.67 million, significantly higher than the year-ago figure of $8.00 million [7] Stock Performance - Northrop Grumman shares have increased by 14.1% over the past month, outperforming the Zacks S&P 500 composite, which saw a 0.7% increase [7]